🔗 Share this article

As the United States undertakes unprecedented adjustments to its immunization guidelines, one figure appears unexpectedly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about Covid shots throughout the pandemic and has focused upon possible fatalities following COVID-19 immunization in her brief position at the Food and Drug Administration.

Scheduled Overhauls to Childhood Vaccine Schedule

Agency leaders were set to announce radical revisions to the pediatric vaccine schedule recently, bringing the US with the Danish immunization schedule, sources say – a significant shift that would place the US out of step with a large portion of the international standard with no evidence for public health gain. The planned update has been delayed until the next year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to present at the event. She was recently named temporary leader of the FDA’s CDER, the fifth individual to head the division this calendar year.

Consolidating Power at the FDA

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and biologics branches as Dr. Høeg and Prasad solidify control at the FDA – and it signals a renewed priority upon dismantling long-standing immunizations at the FDA.

The new acting director has repeatedly called for discontinuing some childhood shot schedules in the US so as to align more similar to Denmark's approach, a society with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

So far comments, she has continued to focus on immunizations – traditionally the domain of Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Concerns Over Background

Høeg has no obvious track record in drug development, regulation or management, which has been standard for past leaders of the CBER. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for leading the CDER, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in running a sizeable institution. She is not an expert in drug approvals.”

Past commissioners of CBER would “understand regulatory frameworks and the underlying principles of drug development”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the type of experience that prior appointees who ran CBER have had.”

This division has an enormous portfolio at the agency, the former commissioner pointed out.

“Everybody just focuses on the innovative therapies, but the off-patent medication office authorizes thousands of off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and more, and every single one must be managed,” Woodcock said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a substantial management aspect to the position, which oversees more than 5,000 personnel. “It’s a huge administrative position, if you execute it properly,” the former official concluded.

Official Statement and Controversial Programs

Regarding inquiries about Høeg’s qualifications and whether this selection indicates more teamwork among regulatory chiefs on vaccines, a press secretary responded that the “questions rely on flawed premises”.

“This background aligns with the functions of her position,” the official stated, noting the months Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the agency head's controversial expedited review system, a controversial rapid drug-approval program that reportedly troubled her preceding directors. “How are these therapies being chosen for this voucher program? Who is making the calls?” Dr. Howard asked. “There is a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the agency seems to be moving towards more relaxed oversight of most medications, aside from immunizations.”

Established Past Work on Immunizations

Regarding vaccines, Høeg has a more documented, if troubling, past, critics said. She published a research paper using unverified public submissions to assess the incidence of myocarditis after Covid immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to suggest Covid vaccines are riskier than they are.

Included in her “wish list” for the incoming federal leadership included revising regulations for novel immunizations and halting “optional” vaccines, she said after the election on a online show. At the FDA, Høeg has according to sources suggested barring young men from receiving COVID-19 vaccinations.

“She’s an all-around ideologue who starts off with her conclusions and tailors the evidence to accommodate the evidence in a highly disingenuous, fraudulent manner,” Howard said.

Taking Control and a “Push for Payback”

Dr. Høeg joined other dissenters, {like|